Inhibition and induction of drug-metabolizing enzymes are the most frequent and dangerous
drug-drug interactions. They are an important cause of serious adverse events that have …

Many genetic variants in drug metabolizing enzymes and transporters have been shown to
be relevant for treating psychiatric disorders. Associations are strong enough to feature on …

Aim: Drug–drug interactions (DDIs) are a widely recognized major cause of adverse drug
reactions, but two other newly described important types of interactions also exist: drug …

This work reports on a complex in silico assessment of the ADME properties of Salubrinal
(S1) and 54 of its structural analogues containing a cinnamic acid residue (S2–S40) or a …

Background: One drug can affect the activity of another when they are administered
together, which can cause adverse drug reactions or sometimes improve therapeutic effects …

Cynomolgus monkeys (Macaca fascicularis, an Old World Monkey) have been widely used
as a non-human primate model in preclinical studies because of their genetic and …

In clinical practice, multiple drugs are often combined in the treatment of patients with
chronic diseases. These associations generally produce drug interactions (DI) with expected …

Sažetak Over the past few decades, physiologically-based pharmacokinetic modelling
(PBPK) has been anticipated to be a powerful tool to improve the productivity of drug …

Amidst the new strategies being developed for the management of type 2 diabetes mellitus
(T2DM) with both established and newer therapies, alpha glucosidase inhibitors (AGIs) have …

Drug-drug interactions (DDIs) can lead to serious and potentially lethal adverse events. In
recent years, several drugs have been withdrawn from the market due to interaction-related …